ArticleMolecular biology reports2026
Anti-cancer efficacy of combined vaccine-strain measles and mumps viruses against colorectal cancer: an experimental study.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to evaluate the oncolytic efficacy of a combination of vaccine-strain measles virus (MeV) and mumps virus (MuV) against colorectal cancer (CRC) cells in vitro and in a nude mouse xenograft model. MATERIALS AND
methodsHT-29 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) and infected with MeV, MuV, or a combination of MeV and MuV (MM; MeV: MuV = 1:1, v/v). Cell viability, synergistic effects, and apoptosis were assessed using MTT and flow cytometry assays, respectively, in vitro. A nude mouse xenograft model was established to evaluate the in vivo oncolytic efficacy of the MM against CRC xenograft tumors.
resultsThe MM demonstrated synergistic effects at 48, 72, and 96 h (CI = 0.473, 0.692, and 0.633, respectively). The MM-treated group showed significantly lower cell viability (p < 0.05) and a markedly higher apoptotic rate (p < 0.01) compared with single-virus-infected groups in vitro. In the xenograft model, the MM-treated group exhibited significantly slower tumor growth (p ≤ 0.001), significantly prolonged survival (p < 0.05), reduced mortality, and increased proportions of innate immune cell populations in the spleen compared with single-virus-treated groups.
conclusionsThe MM demonstrated synergistic and superior oncolytic efficacy against HT-29 colorectal cancer cells compared with single-virus therapies in both in vitro and in vivo xenograft models.
Indexed as
Identifiers
42700211What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.